Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a …

…, NJK Breitborde, H Brenner, ADM Briggs, PM Brooks… - The lancet, 2015 - thelancet.com
Background Up-to-date evidence about levels and trends in disease and injury incidence,
prevalence, and years lived with disability (YLDs) is an essential input into global, regional, …

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013 …

…, NJK Breitborde, H Brenner, AD Briggs, PM Brooks… - The Lancet, 2015 - thelancet.com
Background The Global Burden of Disease Study 2013 (GBD 2013) aims to bring together
all available epidemiological data using a coherent measurement framework, standardised …

Nonsteroidal antiinflammatory drugs—differences and similarities

PM Brooks, RO Day - New England Journal of Medicine, 1991 - Mass Medical Soc
John A. Oates, MD, Editor Alastair JJ Wood, MD, Associate Editor THE nonsteroidal
antiinflammatory drugs (NSAIDs) are very commonly prescribed. This fact reflects the high …

The burden of musculoskeletal disease—a global perspective

PM Brooks - Clinical rheumatology, 2006 - Springer
Musculoskeletal diseases are one of the major causes of disability around the world and have
been a significant reason for the development of the Bone and Joint Decade. Rheumatoid …

Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications

PM Brooks - Current opinion in rheumatology, 2002 - journals.lww.com
Osteoarthritis is a major cause of disability in both the developed and developing world. With
the population aging, the prevalence of osteoarthritis is increasing and its consequences …

[PDF][PDF] Simulation in clinical teaching and learning

JM Weller, D Nestel, SD Marshall, PM Brooks… - Medical Journal of …, 2012 - mja.com.au
2 MJA 196 (9)· 21 May 2012 back to students from the patient perspective. 6 Specifically
trained simulated patients, known as clinical teaching associates, are used in some Australian …

Clinical pharmacokinetics of the salicylates

CJ Needs, PM Brooks - Clinical pharmacokinetics, 1985 - Springer
The use of salicylates in rheumatic diseases has been established for over 100 years. The
more recent recognition of their modification of platelet and endothelial cell function has lead …

Outcomes after hip or knee replacement surgery for osteoarthritis

…, KL Tribe, BG Courtenay, PM Brooks - The Medical Journal of …, 1999 - mja.com.au
… Lyn M March, Marita J Cross, Helen Lapsley, Katherine L Tribe, Brett G Courtenay and
Peter M Brooks … Katherine L Tribe, Clarissa JM Bachmeier, Brett G Courtenay and Peter …

Minimal disease activity for rheumatoid arthritis: a preliminary definition.

GA Wells, M Boers, B Shea, PM Brooks… - The Journal of …, 2005 - jrheum.org
Agreement on response criteria in rheumatoid arthritis (RA) has allowed better standardization
and interpretation of clinical trial reports. With recent advances in therapy, the proportion …

Improving musculoskeletal health: global issues

GM Mody, PM Brooks - Best Practice & Research Clinical Rheumatology, 2012 - Elsevier
Musculoskeletal (MSK) disorders are among the leading reasons why patients consult a family
or primary health practitioner, take time off work and become disabled. Many of the MSK …